Pα+ Psychedelic Bulletin #182: Psychedelics Insiders’ Trump 2.0 Wishlist; Doblin Reflects on Lykos’ Strategy; Polish Psilocybin Study Scores $4M in Funding

December 10, 2024

Inside the FDA’s Psychedelics Journey: Javier Muniz, MD on Breakthroughs, Challenges, and the Future of the Field

December 5, 2024

Psychedelic Drug Development Under Trump 2.0: Health Nominees Signal Uncertain Future

November 30, 2024

Q3’24 Survey: What are Psychedelics Investors Concerned About?

November 27, 2024

Interviews: Meet the Team Who Challenged the DEA on DOI and DOC

November 26, 2024

Q3’24 Survey: What are Psychedelics Investors Excited About?

November 25, 2024

Pα+ Psychedelic Bulletin #181: Last-Minute Changes to Colorado’s Psychedelics Rules; Cybin’s Impressive 12-Month Data Overshadowed by Small N and Controversial Marketing Move

November 22, 2024

Psychedelic Investor Survey Q3 2024

November 19, 2024